Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01237067 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | completed | Phase 1 | 77 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03411980 | Pharmacokinetics and Safety of Vilaprisan in Renal Impairment | completed | Phase 1 | 26 | BayerINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04175067 |
| Evaluation of Thiol Disulfide Balance in Stage 1 Endometrium Cancer |
| completed |
| — |
| 117 |
| Muğla Sıtkı Koçman UniversityOTHER |
| 1 |
| Nov 22, 2019 |
| clinicaltrials |
| NCT00205023 | Disseminated Endometrial Cancer Cells During Sonohysterography | completed | N/A | 25 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00462969 | Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer | completed | N/A | 40 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00543192 | Sexual Functioning in Endometrial Cancer | completed | — | 73 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02096783 | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | completed | N/A | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02470741 | Pilot of Letrozole for Uterine Myomas(PLUM) | completed | Phase 4 | 12 | University of California, San FranciscoOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01377519 | Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids(PROMISe) | completed | N/A | 20 | University of California, San FranciscoOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT02115477 | Lymphedema After Primary Surgery for Endometrial Cancer(LASEC) | completed | — | 262 | Preben Kjolhede, MD, professorOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02676726 | STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer(STELLA-2) | completed | N/A | 208 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02844920 | Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids(OPEN) | completed | — | 37 | GynesonicsINDUSTRY | 4 | Sep 20, 2019 | clinicaltrials |
| NCT04091529 | Tailored Radiofrequency Ablation of Uterine Myomas | completed | N/A | 54 | International Evangelical HospitalOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02578888 | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | completed | N/A | 95 | Albert Einstein College of MedicineOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT02575872 | Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors | completed | N/A | 30 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2019 | clinicaltrials |
| NCT03427671 | OCL 500 Treatment of Women With Symptomatic Uterine Fibroids | completed | N/A | 12 | IMBiotechnologies Ltd.INDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02068820 | Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG | completed | N/A | 200 | AdventHealthOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT01610375 | Telephone Follow-up After Treatment for Endometrial Cancer(TEACUP) | completed | N/A | 149 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Aug 29, 2019 | clinicaltrials |
| NCT01075386 | The Effects of the Endocrine System on Endometrial Cancer(Ghrelin) | completed | — | 75 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00319748 | Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01132820 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01220609 | Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00006089 | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2019 | clinicaltrials |
| NCT00339547 | Risk Factors for Uterine Fibroids: A Case Control Study | completed | — | 1,529 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00095979 | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00096447 | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00301964 | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025220 | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00462826 | VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00723255 | Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00729586 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | completed | Phase 3 | 452 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01637961 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01523678 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | completed | Phase 2 | 108 | Belgian Gynaecological Oncology GroupOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02889848 | Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) | completed | Phase 1 | 15 | Advance Biofactures CorporationINDUSTRY | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00341848 | Postpartum Uterine Regression | completed | — | 374 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Jun 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2019source: clinicaltrials